DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
|
|
- Amanda Knight
- 8 years ago
- Views:
Transcription
1 DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) The prevention of stroke and systemic embolism in atrial fibrillation (AF) with warfarin and New Oral Anticoagulants Warfarin remains the first-line option for anticoagulation in patients with AF at high risk of a stroke. Warfarin is an extremely effective and cost-effective treatment for preventing stroke in AF patients. NOACs represent potentially useful additional treatment options in certain patients, but the paucity of long-term clinical and particularly long-term safety data is of significant concern. NOACs may be suitable for prescribing in primary care as an alternative treatment to warfarin only if a patient s INR cannot be stabilised adequately within the target range with a suitable trial of optimised warfarin treatment; or if a patient is intolerant of warfarin. The benefit of a new oral anticoagulant over warfarin declines as the time in therapeutic range (TTR) on warfarin increases. It may be that warfarin is clinically superior for those with very good control with no difference for those with reasonable control. JAPC and local specialist concerns with NOACs include: o As new agents there is lack of long term safety data. o There is no reversal antidote unlike vitamin K for warfarin. o Lack of monitoring may reduce compliance. is the preferred NOAC formulary choice: o There is no adjustment of dose for age. o may be used with caution in egfr 15 29, whereas is contraindicated in egfr <30. o is once daily whereas is twice daily. o may be put into Monitored Dosage Systems whereas must be left in its original blister. o is licensed for treatment of DVT, and secondary prevention of DVT/PE after DVT whereas is not. The decision about whether to start treatment with rivaroxaban should be made after an informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control. JAPC Derbyshire Guideline The prevention of stroke and systemic embolism in atrial fibrillation with warfarin and New Oral Anticoagulants Page 1 of 12
2 Abbreviations apcc aptt AF ALT CrCl D110 D150 egfr GFR INR LMWH MI NOAC PCC SNRI SSRI TTR ULN VKA Activated prothrombin complex concentrate activated partial thromboplastin time Atrial fibrillation Alanine transaminase Creatinine Clearance 110mg 150mg Estimated glomerular filtration rate Glomerular filtration rate International normalised ratio Low molecular weight heparin Myocardial infarction New oral anticoagulants Prothombin complex concentrate Selective serotonin norepinephrine re-uptake inhibitors Selective serotonin re-uptake inhibitors Time in therapeutic range Upper limit of normal Vitamin K antagonist Content Page Background...3 Aim and objective....3 Recommendations..3 Contraindications....4 Contraindications specific to NOAC...4 Recommended dose schedule o....4 o. 4 Drug interactions o...5 o....5 HASBLED Conversion guidelines for oral anticoagulants.. 6 How to manage bleeding complications.. 7 Discontinuation before surgery..8 References: Appendix 1: GRASP AF and CHADS 2.9 Appendix 2: Summary of NICE TAGs.11 Appendix 3: Summary of Product Characteristics 12 Appendix 4: Summary of NOAC 12 Background Page 2 of 12
3 Atrial fibrillation affects about 1.2% of the population in the United Kingdom and accounts for about a sixth of all strokes 1, 2. Its prevalence increases steeply with age, from 0.5% of those aged years to 10% of those over Strokes are more disabling in patients with atrial fibrillation and have higher 30 day mortality than those of arterial origin. 3,4 Because of the ageing population, the burden of stroke caused by atrial fibrillation is expected to rise sharply over the next few decades unless more effective thromboprophylaxis can be given to the population at risk. 3 When compared with placebo or no antithrombotic treatment, warfarin reduces the risk of stroke by about two thirds in patients with atrial fibrillation. 5 Antiplatelet treatment with aspirin is much less effective than warfarin it reduces the risk of stroke by about a fifth compared with placebo. 5 Guidelines currently recommend warfarin for patients with atrial fibrillation at high risk of stroke (previous stroke or embolism or more than one of the following risk factors: age 75 years, hypertension, diabetes, or congestive cardiac failure), either aspirin or warfarin for those at moderate risk (only one stroke risk factor), and aspirin for patients at low risk for stroke (no stroke risk factors). 6 Stroke is a major cause of morbidity and mortality in the UK. Strokes are more common in individuals living in deprived communities and for those with co-morbidities. The estimated cost of strokes to the UK in 2005/06 was 4.5 billion 7. Aim and Objectives The aim of this policy is to support prescribers in identifying appropriate patients with atrial fibrillation for whom the newer oral anticoagulant drugs as an alternative to current treatment would be an effective and cost effective treatment to prevent embolic events, and to then guide prescribers to prescribe safely. Recommendations JAPC recommends that the NOAC can be considered for the prevention of stroke and systemic embolism in patients with non valvular atrial fibrillation, in whom warfarin is indicated, and who meet the following criteria: A CHADS 2 score of 2 (see appendix1) AND meet NICE criteria (see appendix 2) plus one of the following: Poor control with Warfarin after a 6 month trial (provided compliance is good): o TTR < 50%; o more than 2 INRs >8.0 or more than 3 INR s > 5 in a given 6 month period. or Cannot tolerate warfarin. NOTE: Poor compliance with vitamin K antagonists is not an indication for changing to a NOAC. Intolerance to warfarin is uncommon and changing to another vitamin K antagonist is usually the solution. Contra-indications specific to NOACs Page 3 of 12
4 Hypersensitivity to the active substance or to any of the excipients Creatinine clearance <15 ml/min (egfr <15 ml/min/1.73 m2) Pregnancy and breast feeding Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C Active clinically significant bleeding Hypersensitivity to the active substance or any of the excipients Creatinine clearance <30 ml/min (egfr <30 ml/min/1.73 m2) Pregnancy and breast feeding Liver function tests elevated >2 x ULN Active clinically significant bleeding Organic lesion at risk of bleeding Spontaneous or pharmacological impairment of haemostasis Concomitant treatment with systemic ketoconazole, cyclosporine,dronedarone, itraconazole and tacrolimus is contraindicated in clinical conditions associated with a significant risk of bleeding, such as: current or recent gastrointestinal ulceration malignant neoplasms recent brain or spinal injury recent brain, spinal or ophthalmic surgery recent intracranial haemorrhage oesophageal varices arteriovenous malformations vascular aneurysms major intraspinal or intracerebral vascular abnormalities Recommended dosing schedule of NOACs (According to estimated GFR.) The recommended dose for prevention of stroke and systemic embolism in patients with non-valvular AF is 20mg once daily. Renal function Recommended dose Comments egfr <15 ml/min/1.73 m2 Do not use egfr ml/min/1.73 m2 15 mg once daily Limited clinical data; use with caution. egfr ml/min/1.73 m2 15 mg once daily * Age/ renal function/ concomitant medication Recommended dose Comments Adults aged <75 years 150 mg bd Consider 110 mg bd if high bleeding risk or GI irritation. Adults aged years 150 mg bd If at low thromboembolic risk but high bleeding risk consider 110 mg bd. Adults aged >80 years 110 mg bd Page 4 of 12
5 egfr <30 ml/min/1.73 m2 Do not use egfr ml/min/1.73 m2 150 mg bd Consider 110 mg bd if high bleeding risk or GI irritation. egfr ml/min/1.73 m2 150 mg bd Consider 110 mg bd if high bleeding risk or GI irritation. + Verapamil 110 mg bd * While on treatment renal function should be assessed at baseline then at least once a year, or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate. Drug interactions Interacting drug Dronedarone Systemic azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir) Anticoagulants Antiplatelet drugs/ NSAIDs St John s wort/ rifampicin/ carbamazepine/ phenytoin/ phenobarbital Comments Limited data on combined use. Avoid concomitant use. May increase bleeding risk. Concomitant use with rivaroxaban is not recommended. Risk of bleeding increased. Use with caution. Detailed instructions for the transitions with warfarin are given below. May increase bleeding risk. Use with caution. May reduce rivaroxaban blood levels. Use with caution. Interacting drug St John s wort/ rifampicin/ carbamazepine/ phenytoin Systemic ketoconazole/ cyclosporine/ itraconazole/ tacrolimus Posaconazole Dronedarone Ritonavir Verapamil Amiodarone/ quinidine/ clarithromycin Selective serotonin re-uptake inhibitors (SSRIs) and selective serotonin norepinephrine re-uptake inhibitors (SNRIs) Anticoagulants Antiplatelet drugs/ NSAIDs Comments May reduce dabigatran blood levels. Avoid concomitant use. Use contraindicated with dabigatran. No data on combined use. Concomitant use not recommended. Use contraindicated with dabigatran. No data on combined use. Concomitant use not recommended. Reduce dabigatran to 110 mg bd. Use with caution. May increase dabigatran levels. Use with caution. Increased the risk of bleeding in RE-LY in all treatment groups. Risk of bleeding increased. Avoid concomitant use of other anticoagulants. Detailed instructions for the transitions with warfarin are given below. No parental anticoagulant should be given for 12 hours after last dose of dabigatran. Risk of bleeding increased. This bleeding risk increase is the same as with warfarin, so only use combination where you would with warfarin. Consider 110 mg bd. Page 5 of 12
6 Note Patients should seek urgent medical attention if they fall or injure themselves during treatment, especially if they hit their head, due to the increased risk of bleeding. 9 Those taking other anticoagulants must not take dabigatran/rivaroxaban except during a period where their treatment is being switched to or from the NOACs If compliance is the major factor for poor control this is not resolved with a change to a NOAC. Assessment of bleeding risk should be undertaken before initiating anticoagulant therapy. The simple HAS-BLED bleeding risk score has been developed to help guide choice of therapy. A score 3 indicates high-risk and hence action and regular review of these patients is required (this may include a referral to a haematology consultant led clinic. HAS-BLED bleeding risk score Hypertension >160mmHg 1 Abnormal renal and liver Creatinine >200 1 or 2 function ALT> 3x ULN Stroke/ TIA 1 Bleeding diathesis 1 Labile INR 1 Elderly (>65) 1 Drugs/alcohol 1 or 2 3 indicates high bleeding risk Conversion guidelines of oral anticoagulants (Adopted from Fife Area Drugs and Therapeutics committee) The newer oral anticoagulants should only be considered if there is poor INR control on warfarin as defined above. Conversion from Warfarin to: Warfarin should be stopped and treatment initiated when the INR is 3.0. When converting patients from warfarin, INR values will be falsely elevated after the intake of rivaroxaban. The INR is not valid to measure the anticoagulant activity of rivaroxaban, and therefore should not be used. Warfarin should be stopped and dabigatran started when INR is below 2.0 (usually 3-5 days after discontinuing warfarin for a patient with a stable INR ) Conversion from NOAC to warfarin: It is important to ensure adequate anticoagulation while minimising the risk of bleeding during conversion of therapy. It should be noted that rivaroxaban can contribute to an elevated INR. Warfarin should be given concurrently until the INR is 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by warfarin dosing guided by INR testing. When converting from dabigatran to warfarin, adjust the starting time of warfarin based on creatinine clearance as follows: For CrCL>50mL/min, start warfarin 3 days before discontinuing dabigatran. For CrCL 31-50mL/min, start warfarin 2 days before discontinuing dabigatran. For CrCL 15-30mL/min, start warfarin 1 day before discontinuing dabigatran. Page 6 of 12
7 While on both rivaroxaban and warfarin the INR should NOT be tested earlier than 24 hours after the previous dose but prior to the next dose of rivaroxaban. Once rivaroxaban is discontinued INR testing may be done reliably at least 24 hours after the last dose. Conversion from Parenteral Anticoagulants to: Rivaorixiban should be started 0 to 2 hours before the time of the next scheduled administration of the parenteral medicinal product (LMWH) or at the time of discontinuation of a continuously administered parenteral medicinal product ( e.g. IV unfractionated heparin) Conversion to Parenteral Anticoagulants from: Give the first dose of parenteral anticoagulant at the time the next rivaroxaban dose would be taken For CrCL <15 ml/min, start warfarin 2 days before discontinuing dabigatran. Because dabigatran can contribute to an elevated INR, the INR will better reflects warfarin s effect after dabigatran has been stopped for at least 2 days. should be started 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug ( e.g. IV unfractionated heparin) For patients taking dabigatran, wait 12 hours (CrCL>30mL/min) or 24 hours (CrCL<30mL/min) after the last dose of dabigatran before initiating treatment with a parenteral anticoagulant. How to manage bleeding complications Should bleeding complications arise in a patient receiving a NOAC the next administration dose should be delayed or treatment discontinued as appropriate Discuss with on-call haematology consultant. There is no reversal agent for rivaroxaban or dabigatran. Vitamin K and protamine sulphate do not reverse the effect of rivaroxaban or dabigatran. is not dialyzable. 10 Check the PT and, if available, anti Xa Check the APTT and, if available, the assay (with rivaroxaban standard). Haemoclot thrombin time. has a half-life of Discontinue treatment with dabigatran (half-life approximately 5-13 hours. Delay/omit the 13 hours with normal renal function) next dose of rivaroxaban. If taken within 2 Manage bleeding as per rivaroxaban. There is hours consider activated charcoal. some experimental evidence to support the Management should be individualised role of activated prothombin complex according to the severity and location of the concentrates (FEIBA), PCC or Novoseven. bleed. However, their usefulness in clinical settings Mild bleeding: has not been evaluated and therefore these Local haemostatic measures. alternatives cannot be relied upon. Consider tranexamic acid orally (15 mg/kg QDS) and/or topically (e.g. mouthwash, nasal drops, Around 85% of dabigtran clearance is renal: applied directly to a bleeding point). therefore, maintain adequate diuresis. Moderate severe bleeding: can be dialysed (protein binding is Local haemostatic measures. low), and it may take 6-8 hours to clear Give tranexamic acid IV (15 mg/kg) and/or topically dabigatran this way; however, data supporting (mouthwash, nasal drops, applied directly to this approach is limited. bleeding point). The duration of dialysis may be best guided by Give fluid replacement. Consider FFP (20ml/kg). normalisation of the aptt. Give blood product support as indicated by Hb, other coagulopathy, platelets (if count< 75 x 10 9 /L or antiplatelet agents). Consider use of Prothrombin Complex Concentrate Life threatening bleeding: As for moderate-severe bleeding. Give PCC. Page 7 of 12
8 If the above measures fail to work consider activated prothombin complex concentrate (apcc i.e. FEIBA)) or recombinant factor VIIa (Novoseven). There is currently very limited clinical experience with the use of PCC, apcc and Novoseven in individuals receiving rivaroxaban. The recommendation is based on limited non-clinical data. SURGERY: For emergency surgery consider measures recommended for moderate-severe bleeding. For planned surgery see below. Discontinuation before surgery If an invasive procedure or surgical intervention is required, rivaroxaban should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician. If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention. should be re-started after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established. Renal function (Crcl ml/min) Half-life (hours) (see b) Timing of discontinuation after last dose of dabigatran before surgery Standard High risk of risk of bleeding (see c) bleeding >80 13 (11-24 hours 2-4 days 22) >50 to <80 15 ( hours 2-4 days 34) >30 to <50 18 ( hours 4 days 23) <30 (see 27 ( days >5 days a) 35) Crcl- creatinine clearance a) Contraindicated for use in these patients b) Half-life data from renal impairment study in healthy volunteers 8 c) Types of surgery associated with a high risk of bleeding (or in major surgery where complete haemostasis may be required) include but is not limited to cardiac surgery neurosurgery, abdominal surgery or those involving a major organ. Other procedures such as spinal anaesthesia may also require complete haemostatic function. Other important determinants of bleeding risk include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease), low body weight (<50kg) and concomitant use of antiplatelet therapy. Page 8 of 12
9 References 1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;2: DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92; Lin HJ, Wolk PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27: Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA 2001;285: Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients whohave nonvalvular atrial fibrillation. Ann Intern Med 2007;146: Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidenced-Based Clinical Practice Guidelines (8th edition). Chest 2008;1333:546S. 7. Scarbrough et al. Stroke Stats Strainger J, Rathgen K, Stahle H, et al. Influenceof renal impairment on the pharmacokinetics and pharmacodynamics of ral dabigatran etexilate. Clin Pharmacokinet 2010;49: d5c1 (accessed 01/06/2012). 10. Noakes T. : a guide to new indications. MIMS. April Appendix 1 GRASP AF Query and risk stratification tool is FREE and available for use with all GP clinical systems in England GRASP AF provides a set of MIQUEST queries to identify, for your practice, patients with a diagnosis of AF who are not on warfarin. It calculates their risk of stroke using the validated CHADS 2 scoring system and highlights patients with a CHADS 2 score of 2 or more who are not on warfarin and would benefit from a review to assess the issue of anticoagulation. To find out more about this new tool and to sign up to run the search simply go to CHADS 2 scoring Congestive Cardiac Failure 1 point Hypertension 1 point Age >75 years 1 point Diabetes 1 point Stroke or TIA before 2 points CHADS 2 scores are 0-6; with 0 indicating a low risk of stroke and 6 indicating a very high risk; the scoring and concomitant medication recommended is shown below. These recommendations are used in the GRASP-AF tool and are based on the NICE recommendations for different absolute levels of risk associated with strata of the CHADS 2 scores. (NICE Guideline CG36 Atrial Fibrillation). Page 9 of 12
10 Risk Category CHADS Recommended stroke prevention Score High 2 Oral anticoagulation (OAC) Moderate particularly if age >65 & evidence of vascular 1 Either OAC or Aspirin mg daily Preferred: OAC rather than Aspirin disease No risk factors and age < 65 0 Either Aspirin or no antithrombotic therapy Preferred: no antithrombotic therapy *Target INR 2-3 with time in therapeutic range > 50% CHADS 2 Score Adjusted Annual Stroke Rate (95% confidence interval) Risk rating (low, medium, high) Recommended Treatment ( ) Low Aspirin ( ) Medium Aspirin or Warfarin ( ) Medium Aspirin or Warfarin ( ) High Warfarin ( ) High Warfarin ( ) High Warfarin ( ) High Warfarin Page 10 of 12
11 Appendix 2 Summary of NICE TAGs NICE issued a Technology Appraisal (TA 249) etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in March etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors: previous stroke, transient ischaemic attack or systemic embolism left ventricular ejection fraction below 40% symptomatic heart failure of New York Heart Association (NYHA) class 2 or above age 75 years or older age 65 years or older with one of the following: diabetes mellitus, coronary artery disease or hypertension. 1.2 The decision about whether to start treatment with dabigatran etexilate should be made after an informed discussion between the clinician and the person about the risks and benefits of dabigatran etexilate compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to dabigatran etexilate should be considered in light of their level of international normalised ratio (INR) control. NICE issued a Technology Appraisal (TA 256) for the prevention of stroke and systemic embolism in atrial fibrillation in May is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: congestive heart failure hypertension age 75 years or older diabetes mellitus, prior stroke or transient ischaemic attack. 1.2 The decision about whether to start treatment with rivaroxaban should be made after an informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control. Page 11 of 12
12 Appendix 3: summary of product characteristics These can be found at the following link: Appendix 4 Summary of NOAC (Note that the trials compared different levels of INR rates TTR was 64% in RE-LY and 55% in ROCKET AF) Efficacy in stroke prevention compared to warfarin Reduced risk of bleeding compared to warfarin Overall no difference Superior (150mg bd dose) Non-inferior (110mg bd dose) Evidence for reduced bleeding risk at lower dose. NB Increased risk of GI bleed than warfarin at higher dose which is the usual dose. Overall reduced intra cranial haemorrhage (ICH) Overall no difference Non inferior (ITT analysis) Equivalent to warfarin (except reduced ICH) Reversibility Uncertain. Uncertain (possible data supports use PCC) Dialysable Yes No Dosing bd od Drug interactions P- glycoprotein substrates Simultaneous PGP & CYP-3A4 Use in patients with swallowing difficulties Cannot be crushed Suitability for MDS Not suitable Suitable Cost / year (Costs may vary in different settings because of negotiated procurement discounts) May be crushed and put through NG tube Possibility of using in other conditions NICE approved for orthopaedic prophylaxis. Phase III data shows efficacy in DVT but no NICE appraisal currently planned NICE approved for orthopaedic prophylaxis. Phase III data shows efficacy in DVT and NICE appraisal ongoing. Page 12 of 12
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationVOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256)
Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE PCT, JUBILEE HOUSE, OXFORD BUSINESS PARK SOUTH, OXFORD, OX4 2LH.
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNovel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers
Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers How does it work? Dose and Administration Monitoring Warfarin Dabigatran Rivaroxaban Apixaban Warfarin has an
More informationBirmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement
Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners
More informationXARELTO (RIVAROXABAN) PRESCRIBER GUIDE
XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 16-17 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke
More informationGuidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF
Guidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF Lesley Davey Staffordshire and Lancashire CSU November 2013 (Review November
More informationXARELTO (RIVAROXABAN) PRESCRIBER GUIDE
XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 22-23 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationHow To Use Novel Anticoagulants In Cornwall
PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to guide clinicians on use of novel anticoagulants for stroke
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationXARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING
XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING NOW UPDATED A N D I N C L U D E S A NEW INDICATION Prevention of stroke and systemic embolism in eligible adult patients with non-valvular
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationAll Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation
All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation October 2013 This report has been prepared by a multiprofessional collaborative group, with support
More informationDorset Medicines Advisory Group
Shared Care Guideline for prescribing rivaroxaban in the prevention of adverse outcomes after acute management of acute coronary syndrome in adults INDICATION In accordance with NICE TA335 rivaroxaban
More informationPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery.
PRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTE) FOLLOWING ELECTIVE TOTAL HIP OR KNEE REPLACEMENT SURGERY This guide provides recommendations
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationRivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationPractical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal
More informationXarelto (rivaroxaban) Prescriber Guide November 2012
Xarelto (rivaroxaban) Prescriber Guide November 2012 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationPRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
PRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION This guide provides recommendations for the use of Pradaxa (dabigatran etexilate) in order to minimise the risk
More informationDabigatran and Its Effect on Bleeding Risk
South West Essex Dabigatran Shared Care Guideline (SCG) Dabigatran SCG for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation Introduction Indication and Licensing
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 15 or 20 mg, and the implications of anticoagulant treatment should
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationManagement of bleeding in emergency situations for patients treated with Pradaxa (dabigatran etexilate)
Management of bleeding in emergency situations for patients treated with Pradaxa (dabigatran etexilate) Updated January 2015 2 3 Management of bleeding in emergency situations for patients treated with
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide Simple Protection For More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation 4 Patients
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationVersion 8, 25 April 2013
Hertfordshire Implementation of NICE TAs 249, 256 and 275 Apixaban, dabigatran and rivaroxaban, novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial
More informationNICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues
NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationNOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST NGAIRE IS 70 YEARS OLD AND IN AF. SHE HAS NO MURMURS, NORMAL BLOOD PRESSURE, EGFR OF 65ML/MIN AND NO SIGNIFICANT PAST MEDICAL HISTORY. REGARDING
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationImplementation of NICE TAs 261 and 287
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation
More informationCommon Questions and Answers on the Practical Use of Oral Anticoagulants in Non-Valvular Atrial Fibrillation
Common Questions and Answers on the Practical Use of Oral Anticoagulants in Non-Valvular Atrial Fibrillation South West Medicines Information and Training and Regional Drug and Therapeutics Centre (Newcastle)
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationManagement of non-valvular Atrial Fibrillation
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of non-valvular Atrial Fibrillation Guidelines for anticoagulation apply to paroxysmal, persistent and permanent AF and atrial flutter. Do
More informationGuideline for managing patients on Dabigatran (Pradaxa ) Statewide
Guideline for managing patients on Dabigatran (Pradaxa ) Statewide Custodian: Medication Safety, Medicines Regulation and Quality medicationsafety@health.qld.gov.au Developed by Medication Safety, Medicines
More informationImplementation of NICE TA 249, 256, and 275
Dabigatran, rivaroxaban and apixaban, the new oral anticoagulants (NOACS), for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Implementation of NICE TA 249, 256, and
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationPathway for the management of DVT in primary Care
Pathway for the management of DVT in primary Care Final Version: Approved by NHS DGS CCG: June 2015 This document aims to support practices in DGS CCG in the Management & Treatment of patients with suspected
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationGuideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationCCPN SPAF Tool. www.ccpn.ca STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE
SEPTEMBER 2012 CCPN SPAF Tool STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE Approximately 20% of all strokes are attributable to Atrial Fibrillation (AF). 1 Of these, 20% will result
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide May 2013 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation
More informationRivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists
Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers
More informationGuidelines for the use of existing and New Oral Anticoagulants (NOAC) in the management of Non-Valvular Atrial Fibrillation (AF)
Guidelines for the use of existing and New Oral Anticoagulants (NOAC) in the management of Non-Valvular Atrial Fibrillation (AF) July 14 Version 1 September 2012 Updated to v1.1 due to new contraindication
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More information